Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of anifrolumab in adults with active lupus nephritis
CTR20221549Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anifrolumab in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Sep 2022; status: active.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20221549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221549.